Genus PLC
LSE:GNS
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
Biotechnology
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Realty Income Corp
NYSE:O
|
Real Estate
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
| US |
|
Walt Disney Co
NYSE:DIS
|
Media
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
This note will be permanently deleted.
Genus PLC
Genus PLC
Other Long-Term Assets
Genus PLC
Other Long-Term Assets Peer Comparison
CNTA
EXAI
AUTL
BCYC
IMCR
Competitive Other Long-Term Assets Analysis
Latest Figures & CAGR of Competitors
| Company | Other Long-Term Assets | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Genus PLC
LSE:GNS
|
Other Long-Term Assets
£20.1m
|
CAGR 3-Years
83%
|
CAGR 5-Years
32%
|
CAGR 10-Years
1%
|
|
|
Centessa Pharmaceuticals PLC
NASDAQ:CNTA
|
Other Long-Term Assets
$32.2m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Exscientia PLC
NASDAQ:EXAI
|
Other Long-Term Assets
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Autolus Therapeutics PLC
NASDAQ:AUTL
|
Other Long-Term Assets
$4.4m
|
CAGR 3-Years
-16%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Bicycle Therapeutics PLC
NASDAQ:BCYC
|
Other Long-Term Assets
$6.4m
|
CAGR 3-Years
43%
|
CAGR 5-Years
13%
|
CAGR 10-Years
N/A
|
|
|
Immunocore Holdings PLC
NASDAQ:IMCR
|
Other Long-Term Assets
£11m
|
CAGR 3-Years
18%
|
CAGR 5-Years
26%
|
CAGR 10-Years
N/A
|
See Also
What is Genus PLC's Other Long-Term Assets?
Other Long-Term Assets
20.1m
GBP
Based on the financial report for Dec 31, 2023, Genus PLC's Other Long-Term Assets amounts to 20.1m GBP.
What is Genus PLC's Other Long-Term Assets growth rate?
Other Long-Term Assets CAGR 10Y
1%
Over the last year, the Other Long-Term Assets growth was 58%. The average annual Other Long-Term Assets growth rates for Genus PLC have been 83% over the past three years , 32% over the past five years , and 1% over the past ten years .
You don't have any saved screeners yet
